June 24, 2002
Multimodal intensification therapy for head and neck cancer looks promising, according to results of a phase II trial reported in the June 15 issue of Cancer.
At up to 24 months of follow-up, investigators achieved 100% locoregional control and 93% systemic control with the complex regimen of surgery, radiation, and chemotherapy. They plan to expand testing to multiple institutions.
“We want to go after [head and neck cancer] as decisively and as quickly as possible, and that’s what ‘intensification therapy’ allows us to do,” lead author David E. Schuller, MD, director of the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute in Columbus, Ohio, says in a news release.
Beginning in 1999, 43 surgical candidates with advanced head and neck cancers enrolled in a two-and-a-half month treatment plan consisting of cisplatin and twice-daily radiation for three days preoperatively, more radiation intraoperatively, weekly cisplatin and paclitaxel beginning one week postoperatively, and additional radiotherapy beginning one month postoperatively for an additional four to five weeks.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!